Interim Tumor Progression and Volumetric Changes of Surgical Cavities during the Surgery-to-Radiotherapy Interval in Anaplastic Gliomas: Implications for Additional Pre-radiotherapy Magnetic Resonance Imaging
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This study was designed to investigate the incidence of interim disease progression (IPD) and volumetric changes of the surgical cavity (SC) during the surgery-to-radiotherapy interval (SRI), and eventually assess the value of magnetic resonance imaging (MRI) at the time of radiotherapy (RT) planning in newly diagnosed anaplastic gliomas. Materials and Methods Among 195 anaplastic glioma patients who underwent RT, 121 were evaluable with two separate MRIs during SRI. The presence of IPD was determined using the updated Response Assessment in Neuro-Oncology size criteria. In 84 patients who underwent surgical resection, each SC was contoured by a radiation oncologist and the volumetric changes of the SCs were calculated between the two separate MRIs. Daily rate of change in the SC volume was calculated assuming an exponential and linear change. Results Five of 121 patients (4.13%) demonstrated IPD during SRI, and the incidence was significantly higher in patients undergoing biopsy (vs. surgical resection, 12.9% vs. 1.1%, p=0.015) and in patients with remnant contrast-enhancing tumor after surgery (15.8 vs. 2.0%, p=0.027). The mean daily rate of absolute change in SC was 1.06% (95% confidence interval [CI], 0.89 to 1.23) and 0.89% (95% CI, 0.77 to 1.02) according to the exponential and linear model, respectively. The expected mean volumetric change at 2 weeks were 16.64% (95% CI, 13.77 to 19.52) and 12.51% (95% CI, 10.77 to 14.26), respectively. Conclusion IPD during the SRI is rare in surgically resected anaplastic gliomas. However, pre-RT MRI is essential for accurate RT-target delineation and disease evaluation for patients initiating RT beyond postoperative 2 weeks and undergoing biopsy, respectively.
Abstract
Purpose This study was designed to investigate the incidence of interim disease progression (IPD) and volumetric changes of the surgical cavity (SC) during the surgery-to-radiotherapy interval (SRI), and eventually assess the value of magnetic resonance imaging (MRI) at the time of radiotherapy (RT) planning in newly diagnosed anaplastic gliomas. Materials and Methods Among 195 anaplastic glioma patients who underwent RT, 121 were evaluable with two separate MRIs during SRI. The presence of IPD was determined using the updated Response Assessment in Neuro-Oncology size criteria. In 84 patients who underwent surgical resection, each SC was contoured by a radiation oncologist and the volumetric changes of the SCs were calculated between the two separate MRIs. Daily rate of change in the SC volume was calculated assuming an exponential and linear change. Results Five of 121 patients (4.13%) demonstrated IPD during SRI, and the incidence was significantly higher in patients undergoing biopsy (vs. surgical resection, 12.9% vs. 1.1%, p=0.015) and in patients with remnant contrast-enhancing tumor after surgery (15.8 vs. 2.0%, p=0.027). The mean daily rate of absolute change in SC was 1.06% (95% confidence interval [CI], 0.89 to 1.23) and 0.89% (95% CI, 0.77 to 1.02) according to the exponential and linear model, respectively. The expected mean volumetric change at 2 weeks were 16.64% (95% CI, 13.77 to 19.52) and 12.51% (95% CI, 10.77 to 14.26), respectively. Conclusion IPD during the SRI is rare in surgically resected anaplastic gliomas. However, pre-RT MRI is essential for accurate RT-target delineation and disease evaluation for patients initiating RT beyond postoperative 2 weeks and undergoing biopsy, respectively.
참고문헌 (16)
- Ostrom QT, "CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015", Neuro Oncol, 20, pp.iv1~iv86 (2018)
- Louis DN, "The 2016 World Health Organization classification of tumors of the central nervous system : a summary", Acta Neuropathol, 131, pp.803~820 (2016)
- "Central nervous system cancers (version 1.2019)" (2019)[URL]
- Weller M, "European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas", Lancet Oncol, 18, pp.e315~e329 (2017)
- Cairncross G, "Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma : long-term results of RTOG 9402", J Clin Oncol, 31, pp.337~343 (2013)
- van den Bent MJ, "Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma : long-term follow-up of EORTC brain tumor group study 26951", J Clin Oncol, 31, pp.344~350 (2013)
- van den Bent MJ, "Interim results from the CATNON trial(EORTC study 26053-22054)of treatment with concurrent and adjuvant temozolomide for 1p", 19q non-co-deleted anaplastic glioma : a phase 3, randomised, open-label intergroup study, 2017, pp.390, 1645~1653
- Pierina Navarria, "Hypofractionated Stereotactic Radiation Therapy in Recurrent High-Grade Glioma: A New Challenge", Cancer Research and Treatment, 48(1), pp.37~44 (2016), 대한암학회[DOI]
- Wee CW, "Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy", J Neurooncol, 134, pp.169~175 (2017)
- Pennington C, "A pilot study of brain tumour growth between radiotherapy planning and delivery", Clin Oncol(R Coll Radiol), 18, pp.104~108 (2006)
- Pirzkall A, "Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma", Neuro Oncol, 11, pp.842~852 (2009)
- Villanueva-Meyer JE, "Early tumor growth between initial resection and radiotherapy of glioblastoma : incidence and impact on clinical outcomes", J Neurooncol, 134, pp.213~219 (2017)
- Stensjoen AL, "Growth dynamics of untreated glioblastomas in vivo", Neuro Oncol, 17, pp.1402~1411 (2015)
- Ellingson BM, "Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma", Cancer, 122, pp.1718~1727 (2016)
- Wen PY, "Updated response assessment criteria for high-grade gliomas : response assessment in neuro-oncology working group", J Clin Oncol, 28, pp.1963~1972 (2010)
- Leung D, "Role of MRI in primary brain tumor evaluation", J Natl Compr Canc Netw, 12, pp.1561~1568 (2014)